Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

18.90 +0.28 (+1.50%)
Streaming Delayed Price Updated: 12:19 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zymeworks Inc. - Common Stock

< Previous 1 2 Next >
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August 
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers 
From Zymeworks Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.